Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 16, 2005, Pages 5104-5107

  Guo, Zhiqiang ^a   Tellew, John E ^a   Gross, Raymond S ^a   Dyck, Brian ^a   Grey, Jonathan ^a   Haddach, Mustapha ^a   Kiankarimi, Mehrak ^a   Lanier, Marion ^a   Li, Bin Feng ^a   Luo, Zhiyong ^a   McCarthy, James R ^a   Moorjani, Manisha ^a   Saunders, John ^a   Sullivan, Robert ^a   Zhang, Xiaohu ^a   Zamani Kord, Said ^a   Grigoriadis, Dimitri E ^a   Crowe, Paul D ^a   Chen, Ta Kung ^a   Williams, John P ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLIC AMP; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CORTICOTROPIN RELEASE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; IC 50; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOOD-BRAIN BARRIER; CHO CELLS; CORTICOTROPIN-RELEASING HORMONE; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG DESIGN; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23344454980     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050384+     Document Type: Article

References (16)

1. DeSouza, E. B.; Grigoriadis, D. E. In Psychopharmacology: The Fourth Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven: New York, 1995; pp 505-517.
2. Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999, 33, 181-214.
3. O'Bien, D.; Skelton, K. H.; Owen, M. J.; Nemeroff, C. B. Are CRF receptor antagonists potential antidepressants? Hum. Psychopharmacol. Clin. Exp. 2001, 16, 81-87.
4. Schulz, D. W.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins, J.; Corman, M.; Dunaiskis, A.; Faraci, S.; Schmidt, A. W.; Seeger, T.; Seymour, P.; Tingley, F. D., III.; Winston, E. N.; Chen, Y.; Heym, J. CP-154,526: a potent and selective non-peptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U.S.A 1996, 93, 10477-10482.
5. Webster, E. L.; Lewis, D. B.; Torpy, D. J.; Zachman, E. K.; Rice, K. C.; Chrousos, G. P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996, 737, 5747-5750.
6. Chen, C.; Dagnino, R., Jr.; De Souza, E. B.; Grigoriadis, D. E.; Huang, C. Q.; Kim, K. I.; Liu, Z.; Moran, T.; Webb, T. R.; Whitten, J. P.; Xie, Y. F.; McCarthy, J. R. Design and synthesis of a series of non-peptide high-affinity human corticotropin releasing factor 1 receptor antagonists. J. Med. Chem. 1996, 39, 4358-4360.
7. He, L.; Gilligan, P. J.; Zaczek, R.; Fitzgerald, L. W.; McElroy, J.; Shen, H.-S. L.; Saye, J. A.; Kalin, N. H.; Shelton, S.; Christ, D.; Trainor, G.; Hartig, P. 4-(1,3-Dimethoxyprop-2-ylamino)-2, 7-dimethyl-8-(2,4-dichlorophenyl) -pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF1 receptor antagonist. J. Med. Chem. 2000, 43, 449-456.
8. Hsin, L.-W.; Tian, X.; Webster, E. L.; Coop, A.; Caldwell, T. M.; Jacobson, A. E.; Chrousos, G. P.; Gold, P. W.; Habib, K. E.; Ayala, A.; Eckelman, W. C.; Contoreggi, C.; Rice, K. C. CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential non-peptide corticotropin- releasing hormone type 1 receptor antagonists. Bioorg. Med. Chem. 2002, 10, 175-183.
9. Keller, C.; Bruelisauer, A.; Lemaire, M.; Enz, A. Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab. Dispos. 2002, 30, 173-176.
10. Chen, C.; Wilcoxen, K. M.; Huang, C. Q.; Xie, Y. F.; McCarthy, J. R.; Webb, T. R.; Zhu, Y.-F.; Saunders, J.; Liu, X. J.; Chen, T.-K.; Bozigian, H.; Grigoriadis, D. E. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7- dipropylaminopvrazolo-[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J. Med. Chem. 2004, 47, 4787-4798.
11. 1) antagonists. J. Med. Chem., in press.
12. Beck, J. P.; Arvanitis, A. G.; Curry, M. A.; Rescinito, J. T.; F., Fitzgerald, L. W.; Gilligan, P. J.; Zaczek, R.; Trainor, G. L. Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 967-972.
13. The crystal structure of 16g was determined and is shown in Figure 4 of Supporting Information.
14. De Souza, E. B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J. Neurosci. 1987, 7, 88-100.
15. 2a, receptors. Mol. Pharmacol. 1996, 50, 679-586.
16. Battaglia, G.; Webster, E. L.; De Souza, E. B. Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system. Synapse 1987, 1, 572-581.